Bayer (BAYN) Q3 2025 (Media) earnings summary

Executive summary

• Net sales grew 1% year-over-year in currency and portfolio-adjusted terms, with reported sales down 3% due to €450 million in FX headwinds; group sales reached €9.66 billion in Q3 2025.

• Core EPS for Q3 was €0.57, up 137.5% year-over-year, driven by higher EBITDA and improved financial results.

• Free cash flow for Q3 was €596 million, impacted by higher litigation payments; net financial debt decreased by €600 million sequentially to €32.7 billion.

• Strategic focus on portfolio streamlining, innovation, and operational efficiency, including 13,500 job cuts globally.

• Net income was negative €963 million, mainly due to special charges for litigations, though improved from a €4.18 billion loss in Q3 2024.

Financial highlights

• Core EPS year-to-date reached €4.29, up 7% year-over-year.

• EBITDA before special items for Q3 was €1.51 billion, up 20.8% from prior year.

• Year-to-date EBITDA margin at 26.1%, slightly down due to pricing pressure, FX, and launch investments.

• Special items for litigation-related provisions expected at -€3.5 to -€4 billion for the full year.

• Net financial debt down €2.3 billion year-over-year.

Outlook and guidance

• Confirms full-year 2025 outlook at constant currencies; expects continued FX headwinds into 2026.

• Consumer Health full-year sales growth now expected at -1% to 1% due to challenging U.S. and China markets.

• Crop Science Q4 growth to be driven by glyphosate, with margin dilution expected.

• 2026 focus on ramping Nubeqa, Kerendia, scaling Biantra, and launching Linkwit.